Low pan-immune-inflammation-value predicts better chemotherapy response and survival in breast cancer patients treated with neoadjuvant chemotherapy

Autor: Ulviyya Hasanzade, Birol Ocak, Sibel Oyucu Orhan, Adem Deligonul, Erdem Cubukcu, Sahsine Tolunay, Turkkan Evrensel, Ahmet Z. Sahin, Gorkem Yarbas, Mehmet Refik Goktug, Sibel Kahraman Çetintaş, Kazım Şenol, Zeki Burak Yanasma, Mustafa Sehsuvar Gokgoz
Rok vydání: 2021
Předmět:
0301 basic medicine
Oncology
Turkey
medicine.medical_treatment
Breast cancer
0302 clinical medicine
Antineoplastic Combined Chemotherapy Protocols
Tumor Microenvironment
Stage (cooking)
Mastectomy
Cancer
Aged
80 and over
Univariate analysis
Multidisciplinary
medicine.diagnostic_test
Complete blood count
Middle Aged
Prognosis
Combined Modality Therapy
Neoadjuvant Therapy
Treatment Outcome
Research Design
030220 oncology & carcinogenesis
Tumour immunology
Medicine
Biomarker (medicine)
Female
Adult
medicine.medical_specialty
Science
Immunology
Breast Neoplasms
Article
Young Adult
03 medical and health sciences
Predictive Value of Tests
Internal medicine
Biomarkers
Tumor
medicine
Humans
Peripheral blood cell
Aged
Retrospective Studies
Inflammation
business.industry
medicine.disease
Survival Analysis
030104 developmental biology
T-stage
business
Zdroj: Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
Scientific Reports
ISSN: 2045-2322
Popis: Blood-based biomarkers reflect systemic inflammation status and have prognostic and predictive value in solid malignancies. As a recently defined biomarker, Pan-Immune-Inflammation-Value (PIV) integrates different peripheral blood cell subpopulations. This retrospective study of collected data aimed to assess whether PIV may predict the pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in Turkish women with breast cancer. The study consisted of 743 patients with breast cancer who were scheduled to undergo NAC before attempting cytoreductive surgery. A pre-treatment complete blood count was obtained in the two weeks preceding NAC, and blood-based biomarkers were calculated from absolute counts of relevant cell populations. The pCR was defined as the absence of tumor cells in both the mastectomy specimen and lymph nodes. Secondary outcome measures included disease-free survival (DFS) and overall survival (OS). One hundred seven patients (14.4%) had pCR. In receiver operating characteristic analysis, optimal cut-off values for the neutrophile-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte (PLR), PIV, and Ki-67 index were determined as ≥ 2.34, ≥ 0.22, ≥ 131.8, ≥ 306.4, and ≥ 27, respectively. The clinical tumor (T) stage, NLR, MLR, PLR, PIV, estrogen receptor (ER) status, human epidermal growth factor receptor-2 (HER-2) status, and Ki-67 index were significantly associated with NAC response in univariate analyses. However, multivariate analysis revealed that the clinical T stage, PIV, ER status, HER-2 status, and Ki-67 index were independent predictors for pCR. Moreover, the low PIV group patients had significantly better DFS and OS than those in the high PIV group (p = 0.034, p = 0.028, respectively). Based on our results, pre-treatment PIV seems as a predictor for pCR and survival, outperforming NLR, MLR, PLR in predicting pCR in Turkish women with breast cancer who received NAC. However, further studies are needed to confirm our findings.
Databáze: OpenAIRE
Externí odkaz: